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Abstract
AIM
To assess factors associated with the higher effect of 
metformin on mortality in diabetic colorectal cancer 
(CRC) patients, since the factors related to the effective-
ness of metformin have not been identified yet.
METHODS
Between January 2000 and December 2010, 413 
patients diagnosed with both stage 3/4 CRC and 
diabetes mellitus were identified. Patients’ demographics 
and clinical characteristics were analyzed. The effect of 
metformin on CRC-specific mortality and the interactions 
between metformin and each adjusted factor were 
evaluated.
RESULTS
Total follow-up duration was median 50 mo (range: 
1-218 mo). There were 85 deaths (45.9%) and 72 
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CRC-specific deaths (38.9%) among 185 patients who 
used metformin, compared to 130 total deaths (57.0%) 
and 107 CRC-specific deaths (46.9%) among 228 
patients who did not use metformin. In multivariate 
analysis, survival benefit associated with metformin 
administration was identified (HR = 0.985, 95%CI: 
0.974-0.997, P  = 0.012). Interaction test between 
metformin and sex after adjustment for relevant factors 
revealed that female CRC patients taking metformin 
exhibited a significantly lower CRC-specific mortality 
rate than male CRC patients taking metformin (HR = 
0.369, 95%CI: 0.155-0.881, P  = 0.025). Furthermore, 
subgroup analysis revealed significant differences in 
CRC-specific mortality between the metformin and 
non-metformin groups in female patients (HR = 0.501, 
95%CI: 0.286-0.879, P  = 0.013) but not male patients 
(HR = 0.848, 95%CI: 0.594-1.211, P  = 0.365). There 
were no significant interactions between metformin and 
other adjusted factors on CRC-specific mortality.
CONCLUSION
We showed a strong sex-dependent difference in 
the effect of metformin on CRC-specific mortality in 
advanced stage CRC patients with diabetes. 
Key words: Colorectal cancer; Metformin; Survival; Sex
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Core tip: Evidence from previous studies has identified 
the anti-tumor effect of metformin; however, the 
factors related to effectiveness of metformin in 
diabetic colorectal cancer (CRC) patients have not 
been identified yet. Identifying subgroup patients 
who benefit from metformin treatment is important 
for future clinical application of metformin, and a 
strong sex-dependent difference of metformin effect 
in advanced CRC patients has been identified in this 
present study.
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on colorectal cancer-specific mortality of diabetic colorectal 
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INTRODUCTION
Although the survival rate for colorectal cancer 
(CRC) has increased because of early detection and 
intervention at earlier stages, CRC is still the 3rd most 
common cancer and the 4th leading cause of cancer 
death in the western and Asian countries[1-3]. Cancer 
and diabetes, especially type 2 diabetes mellitus 
(DM), are two of the most prevalent diseases and 
major causes of morbidity and mortality worldwide[4]. 
Despite some argument concerning the influence of 
diabetes on CRC, studies, including meta-analyses, 
have consistently demonstrated that type 2 DM is 
an independent risk factor for CRC and that diabetic 
patients with CRC have worse outcomes than non-
diabetics[4,5]. A possible role for anti-hyperglycemic 
medications in progression and prognosis of CRC has 
been suggested, based on the hypothesis that tumor 
growth is promoted by the trophic action of insulin[4,6]. 
Metformin is broadly used for the treatment of 
type 2 DM, which successfully decreases circulating 
levels of glucose and insulin mainly by improving 
insulin resistance. Evidence from preclinical studies 
has identified the anti-tumor effect of metformin, 
showing inhibition of tumor growth and induction 
of apoptosis in cell lines and animal models of va-
rious cancers[7-9]. Several clinical studies, including 
our previous study[10-18], have shown the ability of 
metformin to reduce the incidence of CRC and improve 
survival of CRC patients. As stated in other studies, one 
of the potential mechanisms of the anti-tumor effect 
of metformin is via activation of AMP-activated protein 
kinase (AMPK). AMPK activation has an inhibitory 
effect on cancer cell growth and new blood vessel 
formation by prohibiting activation of the mammalian 
target of rapamycin (mTOR)[19-21]. With these direct 
cellular effects of metformin, the indirect or systemic 
effect of metformin is relief of insulin resistance-
associated hyperinsulinemia and hyperglycemia, which 
counteracts the dependence of cancer cells on glucose 
as predominant source of energy[20,22]. 
Despite substantial evidence from in vivo and 
in vitro research supporting the possible efficacy of 
metformin as an anti-cancer agent and numerous 
clinical studies investigating the effect of metformin on 
CRC, particular factors or specific groups of patients 
associated with the effectiveness of metformin have 
not been identified. Our study assessed factors that 
may affect the efficacy of the anti-cancer action of 
metformin on CRC-specific mortality in diabetic CRC 
patients. Herein, we selected particular factors that 
might be associated with the “more effective” group 
(those who benefit from metformin for improving CRC-
specific survival) and verified these assumptions using 
interaction analysis.
MATERIALS AND METHODS
Patients
The electronic records of 9472 consecutive patients 
with a diagnostic code of colon or rectal cancer seen 
at a single institution (Severance Hospital, Yonsei 
University, Seoul, Korea) between January 1, 2000 
and December 31, 2010 were identified. A manual 
retrospective review was conducted for all patients to 
identify those with a prior history of DM. Among those 
identified, 1584 had the type 2 diabetes diagnostic 
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code during follow-up, of which 790 were excluded 
based on the following exclusion criteria: type Ⅰ 
diabetes (n = 38), diabetes diagnosed after CRC 
diagnosis (n = 521), incomplete records (including 
medication records) (n = 77), metformin use for less 
than 6 mo (n = 105), and any cancer previous to 
CRC diagnosis (n = 49). According to our previous 
studies, only stage 3 CRC patients[12] and resectable 
stage 4 CRC patients[23] showed a survival benefit from 
metformin. Considering these results, advanced stage 
CRC patients in the latter two groups, denoting stage 3 
and 4 patients, were selected and analyzed; this group 
included 185 DM patients treated with metformin and 
228 DM patients not taking metformin. There were 
135 female patients (32.7%) in the study population.
Patient demographics and clinical characteristics, 
including age at diagnosis, sex, total follow-up duration, 
duration of diabetes, body mass index (BMI), family 
history of colorectal malignancy, smoking history and 
drinking history were obtained from medical records. 
BMI was stratified into “underweight” (BMI < 18.5), 
“normal” (BMI range: 18.5-24.9), “overweight” (BMI 
range: 25.0-29.9) and “obese” (BMI ≥ 30.0), based 
on World Health Organization BMI classification[24]. 
Laboratory findings included plasma glucose levels, 
glycated hemoglobin (HbA1C) levels, and pretreatment 
carcinoembryonic antigen (CEA) levels. Informa-
tion relevant to the CRC diagnosis, such as stage, 
site, histology, differentiation, resection margin, 
lymphovascular invasion, microsatellite instability 
(MSI) status, and treatment modality were reviewed 
via the medical records as well. The use of other 
diabetes medications (sulfonylureas, thiazolidinediones, 
α-glucosidase inhibitors, insulin, etc.) and the use of 
aspirin were also explored. The date of diagnosis of 
CRC was defined as the day of pathologic diagnosis. 
Every enrolled patient had undergone colonoscopy. 
We identified deaths through medical records, and 
determined the cause of death in all cases.
The institutional review board of Severance Hospital, 
Yonsei University, Seoul, Korea approved this study.
Tumor staging and treatment assessment 
All patients were diagnosed with pathologically 
confirmed CRC and were evaluated during their 
baseline visit to Severance Hospital for appropriate 
staging according to the 7th version of the AJCC Tumor/
Node/Metastatic staging system. Treatment modality 
was determined by extent and location of the tumor. 
Based on the National Comprehensive Cancer Network 
guideline, locally advanced tumors or advanced tumors 
with resectable metastatic lesions were treated by 
surgery followed by adjuvant chemotherapy with or 
without radiotherapy, or by neoadjuvant chemotherapy, 
or chemoradiation therapy followed by surgery. Advanced 
CRC with distant metastasis was treated by palliative 
chemotherapy or conservative care.
Statistical analysis
Differences between the metformin and non-metformin 
groups with regard to covariates were determined 
using Pearson’s χ 2 test or Student’s t-test when the 
data were categorical or continuous, respectively. In 
the primary analyses, the odds of overall and CRC-
specific death for patients with diabetes treated with 
metformin and not treated with metformin were 
calculated using univariate logistic regression analysis. 
The multivariate Cox proportional hazards regression 
method was used to estimate HRs and 95%CIs after 
adjustment for patient-related variables, including 
age at diagnosis, sex, stage of cancer, BMI, diabetes 
duration, smoking history, cancer site, and use of 
insulin, aspirin, sulfonylurea and thiazolidinedione. 
Survival curves were generated using the Kaplan-
Meier method and were compared using log-rank 
statistics. In the secondary analyses, interaction 
analyses of Cox regression results were performed 
to reveal the factors associated with metformin use. 
These variables included age at diagnosis (≥ 50 or 
< 50), sex (male or female), smoking history (yes or 
no), tumor stage (Ⅲ or Ⅳ), site (colon or rectum), 
sulfonylurea use (yes or no), insulin use (yes or no), 
and DM duration (years). 
All p values were two sided, with a p < 0.05 con-
sidered significant. Most of the statistical analyses 
were performed using SPSS version 21.0 (SPSS, Inc., 
Chicago, IL, United States). SAS version 9.2 (SAS Inc., 
Cary, NC, United States) was used when identifying 
the cut-off value of metformin duration that provided 
the best fit of the log-rank test statistics of overall and 
CRC-specific survival.
RESULTS
Patients’ demographics and clinical characteristics
The metformin and non-metformin groups had similar 
patient demographics and clinical characteristics (Table 
1). The median age of patients was 64 years (range: 
33-91 years). Baseline characteristics, including age 
at diagnosis, sex, BMI, familial history of cancer, 
smoking and drinking history, were not significantly 
different between the metformin group and the non-
metformin group. Factors associated with cancer, 
including tumor stage, tumor site (colon or rectum), 
tumor differentiation, resection margin positivity, 
MSI status, and pretreatment CEA level were not 
significantly different between the two groups. Clinical 
characteristics associated with diabetic severity status, 
such as HbA1C levels and duration of diabetes, were 
similar between the two groups; however, serum 
fasting glucose levels were lower in the non-metformin 
group compared to the metformin group (143.8 mg/dL 
vs 132.4 mg/dL, p = 0.012). 
The use of other diabetes medications, including 
insulin, sulfonylurea and thiazolidinedione, was 
also investigated, because the status of individuals 
taking these medications could reflect later stage 
diabetes, and these medications could be associated 
with tumorigenesis and prognosis. The use of these 
5198 July 28, 2017|Volume 23|Issue 28|WJG|www.wjgnet.com
Park JW et al . Sex-dependent effect of metformin in colorectal cancer
5199 July 28, 2017|Volume 23|Issue 28|WJG|www.wjgnet.com
treatment modality used for CRC between the two 
groups.
Metformin use and survival analysis
The median follow-up duration was 50 mo (range: 
1-180 mo). With respect to the entire cohort, there 
were 129 (31.3%) recurrences, 215 (52.0%) total 
deaths, and 179 (43.3%) CRC-specific deaths. With 
medications was not significantly different between the 
two groups, with the exception of insulin use, which 
was lower in the metformin group than in the non-
metformin group (9.2% vs 16.2%, p = 0.035). Aspirin, 
a drug known to have beneficial effects in cancer 
survival, was also evaluated and its use was statistically 
different between two groups (27.0% vs 17.1%, p 
= 0.015). Meanwhile, there was no difference in the 
Table 1  Patient demographics and baseline clinical characteristics n  (%)
Metformin group, n  = 185 Non-metformin group, n  = 228 P value
Age at diagnosis in yr, mean ± SD     63.5 ± 8.789     63.49 ± 10.218 0.991
   < 50 12 (6.5) 27 (11.8) 0.064
   ≥ 50 173 (93.5) 201 (88.2)
Sex 0.921
   Male 125 (67.6) 153 (67.1)
   Female 60 (32.4) 75 (32.9)
DM duration in yr, median (range) 8 (1-120) 6 (1-40) 0.068
Family history of CRC 8 (4.3) 13 (5.7) 0.526
BMI in kg/m2, mean ± SD 23.6 ± 3.0 23.5 ± 3.0 0.596
   Normal < 25 148 (80.0) 173 (76.5) 0.300
   Overweight 25-30 33 (17.8) 51 (22.6)
   Obese ≥ 30 4 (2.2) 2 (0.9)
Smoking 0.371
   Never-smoker 89 (48.1) 123 (53.9)
   Ex-smoker 42 (22.7) 40 (17.5)
   Current smoker 54 (29.2) 65 (28.5)
Alcohol 0.556
   None 82 (44.3) 112 (49.1)
   < 1 drink/d 42 (22.7) 51 (22.4)
   ≥ 1 drink/d 61 (33.0) 65 (28.5)
Aspirin use 50 (27.0) 39 (17.1) 0.015
Insulin use 17 (9.2) 27 (16.2) 0.035
Sulfonylurea use 116 (62.7) 153 (67.1) 0.350
Thiazolidinedione use 18 (9.7) 12 (5.3) 0.082
CEA in ng/mL, median (range) 4.7 (0.2-9100.0) 6.4 (0.1-5946.0) 0.359
HbA1c, mean ± SD     8.7 ± 16.7   7.3 ± 1.4 0.349
Glucose in mg/dL, AC ± SD 143.8 ± 46.1 132.4 ± 41.1 0.012
Cholesterol in mg/dL, total ± SD 167.9 ± 47.8 164.6 ± 39.6 0.483
Tumor stage 0.110
   Ⅲ 136 (73.5) 151 (66.2)
   Ⅳ 49 (26.5) 77 (33.8)
Tumor site 0.940
   Colon 106 (57.9) 130 (58.3)
   Rectum 77 (42.1) 93 (41.7)
Histology 0.001
   Adenocarcinoma 177 (97.8) 199 (89.6)
   Mucinous carcinoma 4 (2.2) 23 (10.4)
Differentiation 0.155
   Well differentiated 13 (7.4) 16 (7.8)
   Moderately differentiated 148 (84.6) 174 (84.5)
   Poorly differentiated 14 (8.0) 12 (5.8)
Resection margin + 3 (1.7) 1 (0.6) 0.371
Lymphovascular invasion 56 (25.9) 76 (50.0) 0.031
MSI state 0.670
   MSi 78 (89.7) 68 (90.7)
   MSI-low 6 (6.9) 6 (8.0)
   MSI-high 3 (3.4) 1 (1.3)
Treatment modality 0.160
   Resection only 9 (4.9) 20 (8.8)
   Resection + adjuvant chemotherapy 115 (63.2) 126 (55.3)
   Resection + chemoradiotherapy 22 (12.1) 24 (10.5)
   Neoadjuvant chemotherapy + resection 17 (9.3) 17 (7.5)
   Chemotherapy only 17 (9.3) 35 (15.4)
   Conservative care 2 (1.1) 6 (2.6)
BMI: Body mass index; CEA: Carcinoembryonic antigen; CRC: Colorectal cancer; DM: Diabetes mellitus; MSI: Microsatellite instability.
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respect to metformin use, there were 85 (45.9%) 
total deaths and 72 (38.9%) CRC-specific deaths 
among 185 patients who used metformin, compared 
with 130 (57.0%) total deaths and 107 (46.9%) CRC-
specific deaths among 228 patients who did not use 
metformin. The estimated 5-year CRC-specific survival 
rates were 65.4% and 52.4% for the metformin and 
non-metformin groups, respectively, and 10-year 
CRC-specific survival rates were 50.8% and 43.1%, 
respectively. These results were significantly different 
(HR = 0.724, 95%CI: 0.537-0.976, p = 0.032) (Figure 
1A). For the metformin and non-metformin groups, 
the estimated 5-year overall survival rates were 60.8% 
and 47.9% respectively, and the 10-year overall 
survival rates were 45.8% and 33.8% respectively, 
also showing significant differences (HR = 0.706, 
95%CI: 0.537-0.929, p = 0.013) (Figure 1B).
In addition, we used the duration of metformin 
treatment in multivariate survival analysis, and showed 
this factor to be an independent predictor for CRC-
specific mortality in diabetic patients with advanced 
CRC after adjustment of clinically relevant factors (HR 
= 0.985; 95%CI: 0.974-0.992, p = 0.012). BMI (HR 
= 0.514, 95%CI: 0.287-0.919, p = 0.025), tumor 
stage (HR = 8.401; 95%CI: 5.285-13.355, p < 0.001), 
and HbA1C level (HR = 1.015, 95%CI: 1.004-1.027, p 
= 0.01) were also revealed as independent predictive 
factors (Table 2).
We performed another analysis with the metformin 
group only, using total duration of metformin treat-
ment. The results showed that improvement of CRC-
specific (HR = 0.976, 95%CI: 0.948-0.995, p = 
0.012) and overall survival rates (HR = 0.982, 95%CI: 
0.967-0.997, p = 0.019) was associated with longer 
duration of metformin treatment, after adjustment of 
clinically relevant factors, including age at diagnosis, 
sex, medication history, tumor stage, tumor site, 
diabetes duration, and HbA1C. Analysis using Contal 
and O’Quigley’s method[25] revealed that the cut-off 
value for metformin treatment duration that fit the 
CRC-specific survival statistics was 22 mo.
Interaction analysis of survival benefit from metformin 
treatment
To determine the subgroup with the greater metformin 
effect, interaction tests between metformin and each 
clinical factor were performed, after adjustment for 
other covariates including age at diagnosis, sex, BMI, 
medication use, stage, site, diabetes duration, and 
HbA1C. Interaction tests between metformin and 
sex with adjustment for relevant factors revealed 
that female CRC patients treated with metformin 
exhibited a significantly lower CRC-specific mortality 
rate compared to male CRC patients treated with 
metformin (HR = 0.369, 95%CI: 0.155-0.881, p = 
0.025) (Table 3). 
Subgroup analysis based on sex was performed 
and showed a significant difference in CRC-specific 
mortality between the metformin and non-metformin 
groups for females (HR = 0.013, 95%CI: 0.286-0.879, 
p = 0.013) (Figure 2B), while there was no significant 
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Figure 1  Colorectal cancer-specific survival and overall survival 
according to metformin treatment in colorectal cancer patients with 
diabetes mellitus. A: Colorectal cancer-specific survival according to metformin 
treatment; B: Overall survival according to metformin treatment. 
Metformin group
Non-metformin group
Metformin group
Non-metformin group
Table 2  Multivariate logistic regression analysis for colorectal 
cancer-specific mortality
HR 95%CI P  value
Age at diagnosis of ≥ 50 
or < 50
0.723 0.312-1.675 0.449
Sex, female or male 0.592 0.357-0.982 0.042
BMI of ≥ 25 or < 25 0.514 0.287-0.919 0.025
Smoking history as yes 
or no
0.681 0.359-1.291 0.239
Aspirin use as yes or no 0.802 0.455-1.415 0.446
Metformin treatment 
duration in mo
0.985 0.974-0.997 0.012
Sulfonylurea use as yes 
or no
1.300 0.798-2.120 0.292
Insulin use as yes or no 1.041 0.511-2.121 0.912
Stage Ⅳ or Ⅲ 8.401   5.285-13.355 < 0.001
Site as rectum or colon 0.823 0.521-1.299 0.403
Pathology 0.801 0.238-2.701 0.721
Diabetes duration 0.968 0.935-1.001 0.059
HbA1C 1.015 1.004-1.027 0.010
BMI: Body mass index; CRC: Colorectal cancer.
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difference between the two groups for males (HR 
= 0.365, 95%CI: 0.594-1.211, p = 0.365) (Figure 
2A). Interaction analysis of metformin with other 
adjusted factors did not show any significant difference 
in CRC-specific mortality (Table 3). Intriguingly, 
as documented earlier, the duration of metformin 
treatment affected both CRC-specific mortality and 
overall mortality; however, the mean duration of 
metformin treatment between males and females was 
not significantly different (33.76 ± 24.45 mo for males 
and 28.05 ± 20.59 for females, log rank p = 1.06). 
Subgroup analysis based on metformin treatment 
showed that female patients had significantly lower 
CRC-specific mortality than males in the metformin 
group (HR = 0.332, 95%CI: 0.144-0.764, p = 0.009), 
while the non-metformin group showed no significant 
difference in CRC-specific mortality between male and 
female patients (HR = 0.73, 95%CI: 0.38-1.402, p = 
0.345).
DISCUSSION
Two of the most common diseases worldwide, DM 
and CRC, share numerous risk factors. Previous 
studies, including meta-analyses, demonstrated the 
association between DM and increased risk of CRC; 
moreover, metformin, one of the most commonly 
prescribed anti-diabetes agents, improved survival of 
CRC patients[11,12,14,16,18]. We previously showed that 
CRC patients with diabetes treated with metformin had 
lower mortality than those not treated with metformin, 
and that metformin treatment was associated with 
a decreased incidence of colorectal adenomas in 
diabetic patients with previous CRC[12,26]. Furthermore, 
we showed an association between the metformin 
treatment in stage IV CRC patients with diabetes 
and lower risk of tumor recurrence after curative 
resection[23]. However, there has been no study that 
investigated the specific subgroup within CRC patients 
with diabetes who obtained a survival benefit from 
metformin use. In the present study, we aimed to 
determine the particular subgroup among diabetic CRC 
patients that could benefit from the anti-cancer effect 
of metformin and discovered that sex was the single 
clinical factor that predicted improved survival related 
to metformin treatment. In addition, by including 
the duration of metformin treatment as a factor, we 
showed that longer duration of metformin treatment 
was associated with improved CRC-specific and overall 
survival. 
Metformin treatment has been associated with 
decreased risk and improved survival of DM patients 
with various types of cancer, including colorectal, 
pancreatic, liver, ovarian, breast, and endometrial[11,18]. 
The mechanism of action of metformin as an anti-
cancer drug has not been clearly identified, although 
a shared pathogenesis for DM and some cancers 
is possible, e.g., beta oxidation of fatty acids or 
mitochondrial function[22]. One of the most well-
known mechanisms of metformin is the stimulation 
of peripheral AMPK with decreased hepatic glu-
coneogenesis, increased insulin sensitivity, and hepatic 
fatty acid oxidation[20]. Under physiological conditions, 
AMPK is an intracellular energy sensor and is activated 
when the cellular AMP/ATP ratio increases. AMPK 
activation leads to inhibition of mTOR signaling. mTOR 
phosphorylation is mainly involved in cell growth, 
cell cycle progression, and angiogenesis. Inhibition of 
mTOR signaling can be an excellent cancer therapy 
target, as the mTOR pathway is commonly decontrolled 
in numerous types of cancer, and activation of this 
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Figure 2  Colorectal cancer-specific survival based on sex. A: CRC-specific 
survival according to metformin treatment in males; B: CRC-specific survival 
according to metformin treatment in females. CRC: Colorectal cancer.
Metformin group
Non-metformin group
Metformin group
Non-metformin group
Table 3  Interaction analysis of metformin and relevant 
factors on colorectal cancer-specific mortality
HR 95%CI P  value
Metformin-Sex 0.369 0.155-0.881 0.025
Metformin-BMI 1.000 0.974-1.026 0.972
Metformin-Site 0.941 0.441-2.006 0.875
Metformin-HbA1c 0.999 0.926-1.078 0.979
BMI: Body mass index.
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pathway is associated with poor prognosis and 
resistance to chemotherapy[21,27,28]. Other suggested 
anti-cancer mechanisms of metformin include reduced 
insulin growth factor-1, inhibition of angiogenesis, 
apoptosis, and induction of cell cycle arrest[6,29,30]. 
In our study population, females had a higher 
survival rate associated with metformin treatment after 
adjustment of other clinically significant factors. No 
other studies have reported the interaction between sex 
and survival benefit from metformin in diabetics with 
CRC. However, the study by Lee et al[18] of a cohort of 
800000 Taiwanese showed that metformin effectively 
reduced the incidence of CRC in diabetic women and 
liver cancer in diabetic men, which suggested that sex 
could be an important interaction factor. Numerous 
explanations for this phenomenon can be suggested, 
and the higher survival rate of females compared 
to males among patients with CRC should initiate 
additional studies. 
A Japanese study of 82402 patients with invasive 
CRC who had undergone surgery between 1985 and 
2004 revealed a reduced risk of CRC-specific death for 
females relative to males that persisted over time[31]. 
McArdle et al[32] reported that overall survival and CRC-
specific survival was significantly higher in females 
among patients who underwent elective surgery, 
after adjustment of clinical covariates. One study 
conducted in Israel by Purim et al[33] also reported sex-
age interactions with the incidence of CRC and survival 
of CRC patients showed lower incidence and better 
prognosis for females. The answer for this superior 
CRC survival in females compared to males is usually 
related to female sex hormone status, particularly 
serum estrogen levels[31,34,35]. 
Circulating levels of 17b-estradiol (E2), the main 
estrogenic compound, are exceedingly higher in females 
compared to males and decrease with increasing age. 
While females are exposed to relatively high levels of 
endogenous E2 between adolescence and the 4th or 
5th decade of life, in males, E2 levels remain low and 
steady, and drop minimally with aging. However, after 
menopause, serum E2 levels of females decline to 
levels similar to those of males. Moreover, the effect 
of estrogen on the gastrointestinal tract is well known, 
and in esophageal, gastric, and colon cancers, which 
have higher incidence and mortality rates among 
males, the role of estrogen has been investigated[36,37]. 
Wang et al[38] reported that people at risk of esophageal 
cancer have low levels of estrogen compared to healthy 
subjects. This finding was supported by experimental 
studies showing that estrogen regulates growth, cell 
differentiation, and cell function in the gastrointestinal 
tract. The possible role of estrogen in CRC development 
has been suggested by several lines of epidemiological, 
clinical and experimental evidence; however, the effect 
of estrogen in the progression of CRC has not been 
clearly identified[37,39]. 
With respect to metformin and female hormones, 
we hypothesized that metformin acts on the estrogen 
pathway to affect progression of CRC. This can be 
inferred from another result of Cossor et al[40], showing 
no significant survival benefit of metformin in post-
menopausal females. Reports of the anti-cancer effect 
of metformin in estrogen receptor (ER)-positive breast 
cancer and the anti-estrogenic effect of metformin in 
control of abnormal endometrial proliferative disorders 
support this hypothesis[41,42]. The decrease in ER ex-
pression in tumors from females with endometrial 
cancer and DM treated with metformin compared 
to women treated with insulin also supports this 
hypothesis[42]. In addition, metformin repressed protein 
and mRNA expression of E2/ERα-regulated genes to 
a greater degree than tamoxifen, which resulted in 
inhibition of cell proliferation of ERα-positive breast 
cancer cells[41]. 
Interestingly, estrogen (E2) primarily prevented 
the development of CRC; however, in CRC patients, E2 
promoted cancer progression[43]. Proliferation of CRC 
cells is known to be mediated by ERα, while the level 
of ERα expression is usually low in normal colon tissue 
and CRC tissue[43]. However, when the expression 
of ERβ in cancer cells decreases and the ratio of 
ERα/ERβ rises, ERα expression becomes dominant 
and results in cell proliferation and inhibition of 
apoptosis[43,44]. Interestingly, studies have demonstrated 
sex differences in ER expression in CRC[44,45]. Nüssler 
et al[44] reported a significant increase in ERα protein 
expression in males but not in females, while there 
was no significant difference in ERα and ERβ protein in 
normal colon mucosa between males and females. In 
the same study, ERβ protein expression in CRC cells was 
significantly decreased in both males and females, but 
far more in males[44]. 
Another study conducted by Press et al[45] reported 
the correlation between ERβ protein expression in 
CRC cells, overall survival and sex. Higher ERβ protein 
expression was associated with better overall survival 
in females but worse survival in males[45]. From these 
reports, we inferred that ER status in CRC tissue 
might have a role in cancer progression that could be 
different between males and females. The effect of 
metformin might be related to estrogen, regulation 
of ERα or ERβ expression, or, possibly, E2/ERα ratio 
as well. Although these relationships have not been 
elucidated thus far, we postulate that our findings 
provide the basis for future studies.
As confounding factors, DM severity and treatment 
with other drugs could affect the survival benefit 
conferred by metformin. Severity and duration of 
DM are important factors for cancer progression, 
considering that persistent hyperglycemia and hy-
perinsulinemia might alter the immune system and 
cause a chronic pro-inflammatory condition[4,5]. This 
pathologic state is due to the metabolic abnormalities 
that characterize diabetes, especially under conditions 
of poor metabolic control. In the present study, we 
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measured glycated hemoglobin to represent the 
severity of DM, and total duration since diagnosis of 
DM. In addition, other anti-hyperglycemic agents may 
conceal or diminish this metformin-related cancer 
protection. 
Therefore, we adjusted DM severity and duration, 
along with other anti-hyperglycemic agents, to assess 
the dose-dependent survival benefit of metformin. 
Several studies have investigated the relationship 
between metformin duration or dosage-related nume-
rical values and the incidence of CRC. While there are 
some discrepancies between the study results, one 
study showed that patients treated with metformin for 
over 3 years showed a significantly reduced relative risk 
of CRC (HR = 0.643, 95%CI: 0.490-0.845) compared 
to patients not treated with metformin[46]. Interestingly, 
Lee et al[18] demonstrated that total cancer incidence 
was significantly associated with mean daily dose of 
metformin. Furthermore, subgroup analysis of males 
and females showed other intriguing results; only the 
hazard ratio of liver cancer incidence was significantly 
associated with mean daily dose of metformin in 
males, while CRC incidence was significantly associated 
with mean daily dose in females[18]. Our study results 
showed the relationship between the cumulative effect 
of metformin and CRC-specific survival. In addition, 
duration of DM since diagnosis, duration of metformin 
treatment, and level of glycated hemoglobin were not 
significantly different between males and females, 
which showed that the severity of DM or months of 
metformin treatment had no effect on the sex-related 
interaction.
While this study provided notable associations 
between metformin treatment and sex in the survival 
of CRC patients with DM, there were some limitations. 
First, we could not capture metformin treatment non-
compliance, which could have resulted in exposure 
misclassification and biased the results toward the 
null hypothesis. Additional study limitations included a 
small sample size, which reduced the power to detect 
significant differences in survival, even though our 
findings were similar to previous studies of metformin 
treatment and CRC outcomes. Data regarding the 
specific cancer location, such as right or left sided, 
were not available for this study. Location of cancer is 
an important difference between males and females, 
where females develop more proximal, and males 
more distal colon and rectal cancers[47,48]. Finally, 
because the data analyzed in this study population 
were collected from a tertiary medical care unit, 
results may not be generalizable to the general 
population. Further studies with a larger and more 
diverse population should be conducted to strengthen 
the relationship between sex and the anti-cancer effect 
of metformin in CRC patients with DM. Moreover, 
future prospective studies should consider this sex-
specific difference when performing clinical trials using 
metformin as an additive therapeutic agent for diabetic 
and non-diabetic CRC patients.
COMMENTS
Background
Previous studies showed metformin use was associated with decreased 
colorectal cancer (CRC) mortality. The identification of factors associated with 
the effect of metformin on mortality in diabetic CRC patients will provide useful 
information when applying metformin in cancer treatment.
Research frontiers
Despite substantial evidence from in vivo and in vitro research supporting 
the possible efficacy of metformin as an anti-cancer agent and numerous 
clinical studies investigating the effect of metformin on CRC, particular factors 
or specific groups of patients associated with the effectiveness of metformin 
have not been identified. Herein, authors selected particular factors that might 
be associated with the “more effective” group, i.e., those who benefit from 
metformin for improving CRC-specific survival, and verified these assumptions 
using interaction analysis.
Innovations and breakthroughs
The authors discovered that sex was the single clinical factor that predicted 
improved survival related to metformin treatment. This is also the first study 
to report the interaction between sex and survival benefit from metformin in 
diabetics with CRC. Furthermore, results of this study showed the relationship 
between the cumulative effect of metformin and CRC-specific survival.
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Peer-review
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